Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy

Core Insights - Capricor Therapeutics is hosting a webinar on July 29, 2025, to discuss the status of its Biologics License Application (BLA) for Deramiocel and provide information on cardiomyopathy in Duchenne Muscular Dystrophy (DMD) [1][2] - Deramiocel is an allogeneic cardiac-derived cell therapy currently in late-stage development for DMD, demonstrating potent immunomodulatory and anti-fibrotic actions [3][5] - Capricor has entered an exclusive commercialization agreement for Deramiocel in the U.S. and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [5] Company Overview - Capricor Therapeutics focuses on developing cell and exosome-based therapeutics for rare diseases, with a commitment to innovative treatments [3] - The company utilizes its proprietary StealthX™ platform for preclinical development in various therapeutic areas, including vaccinology and targeted delivery [3] Webinar Details - The webinar will include a review of the BLA status for Deramiocel and a Q&A session with the community [1] - A replay of the webinar will be available on the Parent Project Muscular Dystrophy (PPMD) website [2]